< Back to previous page
Researcher
Karen van Hoeve
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Aug 2017 → 10 Aug 2020
Publications
1 - 10 of 22
- Nausea is the only symptom associated with delayed gastric emptying in pediatric functional dyspepsia patients(2023)
Authors: Karen van Hoeve, Jan Tack, Ilse Hoffman
- Recurrent oral aphthosis as the solitary clinical manifestation of Crohn’s disease in children: a case report(2023)
Authors: Ilse Hoffman, Karen van Hoeve
Pages: 97 - 99 - A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Authors: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pages: 896 - 908 - Renal manifestations in inflammatory bowel disease: a systematic review(2022)
Authors: Karen van Hoeve, Ilse Hoffman
Pages: 619 - 629 - Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy(2022)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Marc Ferrante, Séverine Vermeire
Pages: 150 - + - Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place(2020)
Authors: Karen van Hoeve, Séverine Vermeire
Pages: 449 - 461 - Optimisation of long-term outcomes in paediatric inflammatory bowel disease patients: role of therapeutic drug monitoring and endoscopic remission.(2020)
Authors: Karen van Hoeve, Séverine Vermeire, Ilse Hoffman, Ann Gils
- INFLIXIMAB SERUM LEVELS DURING INDUCTION PREDICT LONG-TERM ENDOSCOPIC REMISSION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.(2020)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Marc Ferrante, Séverine Vermeire
Pages: S968 - S968 - Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease(2020)
Authors: Karen van Hoeve, Ilse Hoffman, Marc Ferrante, Séverine Vermeire
Pages: 164 - 172 - Efficacy, pharmacokinetics and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease.(2019)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 317 - 324